-
161
Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis
Published 2022-03-01“…Therefore, LTX-315, or the development of ATP11B-targeting drugs, might improve the efficacy of cancer immunotherapy.…”
Get full text
Article -
162
Ly6E on tumor cells impairs anti-tumor T-cell responses: a novel mechanism of tumor-induced immune exclusion
Published 2024-11-01“…Conclusion Our study illuminated that Ly6E-expressing tumor cells facilitated the accumulation of M2 macrophages in TME, which contributes to CD8+ T cell exclusion and provides new insights for improving efficacy of cancer immunotherapy.…”
Get full text
Article -
163
Injectable supramolecular hydrogel co-loading abemaciclib/NLG919 for neoadjuvant immunotherapy of triple-negative breast cancer
Published 2025-01-01“…Abstract The efficacy of cancer immunotherapy relies on a sufficient amount of functional immune cells. …”
Get full text
Article -
164
Impact of thoracic radiotherapy on first‐line treatment outcomes in ES‐SCLC patients
Published 2024-09-01Get full text
Article -
165
-
166
Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer
Published 2025-02-01“…Current pancreatic cancer immunotherapy focused on alphabeta (αβ) T cells, either through CD3-engaged bispecific antibodies or CAR-T. …”
Get full text
Article -
167
-
168
Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
Published 2025-01-01“…Predicting and preventing irAEs during the early stages of treatment has become a critical research focus in cancer immunotherapy. This study aims to evaluate the predictive value of peripheral blood cell counts for irAEs.MethodsStudies meeting the inclusion criteria were identified through database searches. …”
Get full text
Article -
169
RNA N6‐Methyladenosine‐Binding Protein YTHDFs Redundantly Attenuate Cancer Immunity by Downregulating IFN‐γ Signaling in Gastric Cancer
Published 2025-01-01“…Collectively, these findings highlight how YTHDFs modulate cancer immunity by influencing IFN‐γ signaling through IRF1 regulation, suggesting their viability as therapeutic targets in cancer immunotherapy.…”
Get full text
Article -
170
Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus...
Published 2023-01-01“…Background Oncolytic virus immunotherapy has revolutionized cancer immunotherapy by efficiently inducing both oncolysis and systemic immune activation. …”
Get full text
Article -
171
-
172
Resveratrol contributes to NK cell-mediated breast cancer cytotoxicity by upregulating ULBP2 through miR-17-5p downmodulation and activation of MINK1/JNK/c-Jun signaling
Published 2025-02-01“…This finding identifies RES as a potentially effective therapeutic agent for inhibiting BC progression and optimizing NK cell-based cancer immunotherapy.…”
Get full text
Article -
173
Machine-Learning Parsimonious Prediction Model for Diagnostic Screening of Severe Hematological Adverse Events in Cancer Patients Treated with PD-1/PD-L1 Inhibitors: Retrospective...
Published 2025-01-01“…Our model might enhance early diagnostic screening of irHAEs induced by PD-1/PD-L1 inhibitors, contributing to minimizing the risk of severe irHAEs and improving the effectiveness of cancer immunotherapy.…”
Get full text
Article -
174
Deregulated methylation and expression of PCDHGB7 in patients with non-small cell lung cancer: a novel prognostic and immunological biomarker
Published 2025-01-01“…Its function in lung cancer has not been elucidated.MethodsWe comprehensively investigated PCDHGB7 expression, prognosis, biological function, methylation patterns, and it’s relationship with immune infiltration and immunotherapy response through public datasets (HPA, TCGA, GEO, OncoDB and MEXPRESS). Two lung cancer immunotherapy cohorts from our clinical center were enrolled to detect the relationship between methylation and protein levels of PCDHGB7 in plasma and immunotherapy outcomes.ResultsPCDHGB7 expression was downregulated in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) and associated with tumor prognosis. …”
Get full text
Article -
175
Immunogenic dying cells elicit potent anti-tumor T cell immunity against lung metastasis and tumorigenesis
Published 2025-01-01“…Conclusion Immunization with the ICD dying tumor cells evokes potent tumor-specific T cell immunity, which provides a novel approach for cancer immunotherapy.…”
Get full text
Article -
176
Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy
Published 2025-01-01“…Abstract Background Cancer immunotherapy is a relatively new approach to cancer treatment. …”
Get full text
Article -
177
Arginase-1-specific T cells target and modulate tumor-associated macrophages
Published 2025-01-01“…Background Arginase-1 (Arg1) expressing tumor-associated macrophages (TAMs) may create an immune-suppressive tumor microenvironment (TME), which is a significant challenge for cancer immunotherapy. We previously reported the existence of Arg1-specific memory T cells among peripheral blood mononuclear cells (PBMCs) and described that Arg-1-based immune modulatory vaccines (IMVs) control tumor growth and alter the M1/M2 macrophage ratio in murine models of cancer. …”
Get full text
Article -
178
Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation
Published 2023-01-01“…Furthermore, targeting CEMIP provides an effective strategy for colorectal cancer immunotherapy.…”
Get full text
Article -
179
Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma
Published 2025-02-01Get full text
Article -
180